Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

NCT01808573 is registered in ClinicalTrials.gov with Puma Biotechnology, Inc. as lead sponsor.

NCT NCT01808573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01808573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Lead sponsor
Puma Biotechnology, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 29, 2013
Completion date
December 9, 2019
Enrollment
621 (actual)
Sites
252

Conditions

As the registry lists them; a condition with its own page is linked.

her2+ metastatic breast cancer (mbc)